Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Chiara Cremolini - University of Pisa, Pisa, Italy
Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )
6 Jun 2022

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA
Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA )
5 Jun 2022

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan
Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )
5 Jun 2022

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer

Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )
5 Jun 2022

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - The Peter MacCallum Cancer Centre, Melbourne, Australia )
4 Jun 2022

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia
Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer ( Dr Jeanne Tie - Peter MacCallum Cancer Centre, Melbourne, Australia )
4 Jun 2022

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
14 Apr 2022

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
17 Feb 2022

Tumour agnostic treatments in GI cancer

Dr Nicola Normanno and Dr Katja Schmitz
Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )
1 Feb 2022

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer

Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France
Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer ( Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France )
27 Jan 2022

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )
25 Jan 2022

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
20 Jan 2022